Pitcairn Co. reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 0.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,769 shares of the company’s stock after selling 36 shares during the quarter. Pitcairn Co.’s holdings in Eli Lilly and were worth $393,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Joel Isaacson & Co. LLC increased its stake in Eli Lilly and by 1.5% during the first quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after acquiring an additional 50 shares during the last quarter. Sumitomo Life Insurance Co. grew its stake in shares of Eli Lilly and by 4.4% in the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after buying an additional 1,370 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Eli Lilly and by 7.8% in the second quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock valued at $55,258,000 after buying an additional 48,706 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares in the last quarter. Finally, Stephens Inc. AR grew its stake in shares of Eli Lilly and by 4.5% in the first quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after buying an additional 1,901 shares in the last quarter. Institutional investors own 75.72% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the completion of the transaction, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 990,000 shares of company stock valued at $82,949,650 in the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

Shares of Eli Lilly and Company (LLY) opened at 87.08 on Friday. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09. The firm has a market capitalization of $91.87 billion, a PE ratio of 37.68 and a beta of 0.34. The company has a 50-day moving average price of $82.21 and a 200 day moving average price of $82.15.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.86 EPS. Analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on the company. Morgan Stanley set a $86.00 target price on Eli Lilly and and gave the company a “hold” rating in a research note on Friday. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday. Cowen and Company reiterated a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday. BMO Capital Markets reiterated a “sell” rating and issued a $71.00 target price on shares of Eli Lilly and in a research note on Thursday, September 28th. Finally, Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Monday, July 17th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Eli Lilly and has a consensus rating of “Hold” and an average price target of $88.42.

WARNING: “Pitcairn Co. Has $393,000 Position in Eli Lilly and Company (LLY)” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/pitcairn-co-has-393000-position-in-eli-lilly-and-company-lly/1616771.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.